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Introduction
============

Quality control of newly synthesized glycoproteins involves recognition of misfolded proteins in the ER, where they are either returned to a productive folding pathway or are targeted for degradation ([@bib18]). Terminally misfolded glycoproteins are transferred to the cytoplasm for proteasomal proteolysis, a process termed dislocation ([@bib74],[@bib75]).

How the cell distinguishes between newly synthesized proteins that have not yet acquired their correct folding state and proteins that are terminally misfolded remains a mystery. In yeast, genetic analysis has shown the involvement of a limited set of proteins that contribute to recognition of misfolded proteins and their subsequent degradation. The secretory protein carboxypeptidase Y (CPY), when engineered to yield a misfolded product, CPY\*, has served as a substrate to identify the genetic factors that interfere with its disposal. Der1p was identified as a key player in clearing the yeast ER of misfolded CPY\* ([@bib43]; [@bib30]; [@bib71]; [@bib28]). HMG-CoA reductase, which is a transmembrane protein, has similarly served as a reporter substrate, allowing [@bib27] to define HRD1 and HRD3 as essential for its degradation ([@bib23], [@bib22]).

Hrd1p/Der3p has ubiquitin ligase activity (E3) and forms a complex predominantly with the ubiquitin-conjugating enzymes (E2s) Ubc7p and Ubc1p ([@bib3]), which are themselves recruited by the protein Cue1p ([@bib7]) to the site of degradation. Hrd3p is required for regulating the activity and stability of Hrd1p/Der3p ([@bib59]), but the function of Hrd3p in protein degradation remains obscure. Hrd3p has a large luminal domain that contains different sets of repeated regions that might be involved in substrate recognition or form complexes with chaperones. Apart from the Ring-H2 ligase Hrd1p/Der3p, there are additional ER membrane--resident E3s, such as Doa10p ([@bib65]).

Depending on the topology of the ER degradation substrates, different proteins are required for their clearance ([@bib2]). Substrates with defects in their cytosolic domain require Doa10p in yeast. Substrates with defects in their luminal portion require the ER lectin Htm1p/Mnl1p, the ubiquitin ligase Hrd1p/Der3p-Hrd3p, Der1p, and proteins involved in ER--Golgi trafficking ([@bib70]). The two pathways merge when leaving the ER; extraction of the ubiquitin-modified substrate occurs with the assistance of Cdc48p/p97 and its cofactors Ufd1p and Npl4p, culminating in delivery to the proteasome and proteolysis of the substrate ([@bib50], [@bib51]; [@bib78], [@bib79]; [@bib72]; [@bib58]). Recent studies analyzed the composition of the protein complexes involved. The Doa10p complex contains Ubc7p, Cue1p, Ubx2p, Cdc48p, and its cofactors Ufd1p and Npl4p. These proteins are mainly cytosolic, supporting Doa10p\'s role in clearing proteins with defects in their cytosolic domain. In addition to these proteins, the Hrd1p complex consists of Hrd3p, Der1p, the ER lectin Yos9p, and Usa1p ([@bib13]; [@bib17]). Yos9p has been shown to specifically bind misfolded glycoproteins ([@bib6]; [@bib40]; [@bib66]). Ubx2p recruits Cdc48p to the membrane ([@bib55]). Usa1p is thought to link Der1p to the Hrd1p ligase and thereby assist in clearing luminally misfolded proteins from the ER ([@bib37]).

In mammalian cells, the dislocation pathway is more complex. Because of the lack of a genetic approach, the dissection of the degradation pathway in mammalian cells relies on the use of substrates, such as mutant versions of the cystic fibrosis chloride conductance channel ([@bib73]; [@bib5]; [@bib77]; [@bib41]), of proteins considered terminally misfolded, such as the mutant null Hong Kong (NHK) version of the secretory glycoprotein α1 antitrypsin ([@bib47]) or the truncated and misfolded version of the ER-resident glycoprotein ribophorin (RI), termed RI~332~ ([@bib69]; [@bib15]). Many membrane proteins fail to fold properly for lack of the correct partner subunits, such as the unpaired T cell receptor α chain (TCRα; [@bib35],[@bib36]) or the free immunoglobulin μ chain ([@bib19]).

Many parallels exist between the yeast and the mammalian glycoprotein quality control systems; however, the players in the mammalian system are more numerous. The mammalian version of HRD1 is also an ER membrane--resident ubiquitin ligase ([@bib38]; [@bib54]; [@bib39]), which forms a complex with SEL1L, a mammalian orthologue of yeast Hrd3p ([@bib45]). Additional ubiquitin ligases exist, such as gp78, which has similarity to HRD1 in its Ring finger and interacts with UBC7 via its CUE domain to ubiquitinate TCRα ([@bib20]). There are at least three Der1p homologues in mammals, Derlin-1, -2, and -3, which play roles in the disposal of proteins from the ER ([@bib44], [@bib45]; [@bib56]).

Among the better-studied routes of membrane glycoprotein degradation are the pathways used by human cytomegalovirus (HCMV) to destroy the class I major histocompatibility complex (MHC) heavy chains (HCs; [@bib1]). Class I MHC products serve as a warning system to alert cytotoxic T cells to the presence of virus-derived polypeptides inside the cell. The infected cell, thus, invites attack by the cytotoxic T cell as a means of eradicating the source of the virus ([@bib68]). Large DNA viruses, such as HCMV, are under strong selective pressure to avoid recognition by the immune system. Although widespread amongst the \[herpesviridae as a strategy to avoid detection, HCMV in particular has amassed a set of genes whose products evolved to interfere with assembly and intracellular transport of class I MHC products. Amid the HCMV-encoded immunoevasins, two, US2 and US11, which are small membrane glycoproteins that assist in the degradation of class I MHC HCs, stand out. US2 and US11 catalyze superficially similar reactions, characterized by complex formation of US2 or US11 with their target class I MHC HCs, and subsequent extraction of the class I MHC HCs from the ER, a process referred to as dislocation ([@bib74],[@bib75]). After dislocation, the class I HC is destroyed by the proteasome. In the presence of proteasome inhibitors, a diagnostic intermediate in this pathway is the result of attack by N-glycanase on the newly dislocated class I MHC HCs ([@bib74],[@bib75]; [@bib31]; [@bib9]). This intermediate consists of a fully cytoplasmic, yet intact, class I MHC HC, devoid of its N-linked glycan ([@bib52]). It occurs not only in cells that express US2 or US11, but also in Daudi cells, which are unable to assemble class I MHC products for lack of the light chain β2-microglobulin ([@bib34]; [@bib61]). Similar deglycosylated intermediates have been reported for a misfolded fragment of RI ([@bib15], [@bib16]), but for most other glycoproteins examined, degradation occurs without the obvious production of deglycosylated intermediates.

These observations raise the question as to whether the pathways exemplified by US2- and US11-dependent degradation are indeed emblematic of glycoprotein turnover, as we have argued in the past. The furthest advanced is the characterization of the US11 pathway, for which we identified the Derlin-1 protein as an essential participant ([@bib44]; [@bib80]). Derlin-1, in turn, forms a complex not only with itself and other members of the Derlin family, but also with the mammalian Hrd1p and Hrd3p (SEL1L) homologues, as well as with Cdc48p/p97 ([@bib45]; [@bib81]). The US2 pathway is impervious to the action of a dominant-negative version of Derlin-1, whereas the US11 pathway is inhibited by it ([@bib44]). Direct involvement in mammalian glycoprotein degradation has now been suggested for components of this ER-resident complex, based on interference with degradation of α1 antitrypsin NHK by means of overexpression and knockdowns of Derlins ([@bib56]). Still, in mammalian cells, much of the relevant data stem from the analysis of reactions that depend on the action of the viral accessories US11 and US2.

We analyze the contributions of a mammalian Hrd3p homologue, SEL1L. We show that reduction of the levels of SEL1L by RNA interference results in impairment of US11-mediated dislocation of class I MHC HC molecules. Expression of the same interfering small hairpin RNAs (shRNAs) against SEL1L, however, does not affect the US2 pathway. Expression of SEL1L shRNAs inhibits the degradation of RI~332~, which is a process that occurs independently of the presence of viral accessories. These results allow us to place SEL1L in a more general context of glycoprotein degradation, and suggest that SEL1L might be involved in substrate recognition of misfolded proteins in the ER.

Results
=======

SEL1L is part of a mammalian ER multiprotein complex involved in dislocation ([@bib45]; [@bib81]). SEL1L associates with Derlin-1, -2, p97, and HRD1, as well as with additional proteins that remain to be identified, some or all of which may also play a role in dislocation. Some of these proteins are presumably recruited to the site of dislocation through SEL1L. SEL1L is predicted to be a type I transmembrane protein (Fig. S1, available at <http://www.jcb.org/cgi/content/full/jcb.200605196/DC1>) with 5 N-linked glycans ([@bib8]). Because the bulk of the SEL1L protein is predicted to be in the ER lumen, it is possible that SEL1L first plays a role in substrate recognition and identification of misfolded proteins, and then recruits them to the site of dislocation. We performed coimmunoprecipitations from steady-state radioactive \[^35^S\]methionine/cysteine--labeled cells using mild lysis conditions (2% digitonin) to preserve ER membrane protein complexes, to analyze whether composition of protein complexes with SEL1L are conserved for the cell lines used in this study.

Our earlier observations concern the composition of protein complexes that include the Derlins in the astrocytoma cell line U373 ([@bib45]). We first verified that the types of complexes detected in U373 cells are not cell type--specific, but occur in other cell lines as well ([Fig. 1](#fig1){ref-type="fig"}). We were particularly interested in cell lines that would lend themselves to transient transfection experiments ([Fig. 1](#fig1){ref-type="fig"}, HeLa cells, lanes 1--4) and in multiple myeloma cells ([Fig. 1](#fig1){ref-type="fig"}, MM1.S cells, lanes 5--8), which represent cells with a high secretory capacity, and, presumably, a correspondingly pronounced requirement to clear misfolded proteins from the ER.

![**SEL1L is part of a conserved complex in many cell types.** Immunoprecipitation from digitonin lysates of HeLa (lanes 1--4) or MM1.S (lanes 5--8) cells pulse-labeled for 16 h (steady state) were performed with control rabbit IgG, anti--Derlin-1, anti--Derlin-2, and anti-SEL1L antibodies, respectively. The positions of the relevant proteins are indicated.](jcb1750261f01){#fig1}

When we performed immunoprecipitations with antibodies against Derlin-1, -2, and SEL1L, the composition of the complexes obtained was very similar to that reported for U373 cells ([@bib45]). We conclude that the multiprotein complexes, which were initially identified for U373 cells, are representative of the complexes detected in other, unrelated cell types. The pattern of the protein complexes is equivalent in all tested cell lines, including U373 (astrocytoma), HeLa (epithelial), 293T, MM1.S (multiple myeloma), and C6 (Rat glioma) cells. SEL1L is likely to be a crucial component of a ubiquitous ER-dislocation complex.

When we analyzed the half-life of SEL1L, we found that it decays with a half-life of ∼180 min ([Fig. 2](#fig2){ref-type="fig"}, lanes 1, 3, and 5). SEL1L degradation appears to be proteasome-dependent because it is inhibited by inclusion of the proteasome inhibitor ZL~3~VS ([Fig. 2](#fig2){ref-type="fig"}, lanes 7, 9, and 11). SEL1L remains completely susceptible to endoglycosidase H (EndoH) treatment, suggesting that SEL1L is an ER protein and does not traffic through the secretory pathway ([Fig. 2](#fig2){ref-type="fig"}, lanes 2, 4, 6, 8, 10, and 12).

![**SEL1L is an unstable ER membrane glycoprotein.** Immunoprecipitation from NP-40 lysates of U373 cells pulse-labeled for 20 min and chased for the indicated time points in the absence (lanes 1--6) or presence (lanes 7--12) of ZL~3~VS were performed with anti-SEL1L antibodies. Half of the eluates were treated with EndoH (lanes 2, 4, 6, 8, 10, and 12).](jcb1750261f02){#fig2}

To address whether SEL1L plays a direct role in the process of dislocation from the ER, we generated small hairpin RNAs (shRNAs) that target SEL1L or a control unrelated protein (GFP) using the pRETRO-SUPER in vivo expression system ([@bib11]). The shRNA plasmids reduced SEL1L protein levels to 30% compared with control cells ([Fig. 3 a](#fig3){ref-type="fig"}).

![**shRNAs targeting SEL1L impair US11-mediated dislocation of class I MHC HC.** (a) US11 cells were transduced with virus encoding shRNAs against GFP (control cells) or against SEL1L (knockdown cells) and analyzed for levels of SEL1L by immunoblotting with anti-SEL1L antibodies and anti--protein disulfide isomerase (PDI) antibodies as a loading control. (b) Control and knockdown cells were pulse-labeled for 10 min and chased for the indicated time points. Immunoprecipitation from SDS lysates for class I MHC HC (1), US11 (2), and HRD1 (3) were performed using respective antibodies. (c) Quantitation of the amount of glycosylated to deglycosylated HC from shRNA GFP (control) and shRNA SEL1L (knockdown) cells treated with ZL~3~VS.](jcb1750261f03){#fig3}

We analyzed the stability of class I MHC HCs in cells expressing US11 and the SEL1L shRNAs. The fate of HC is best analyzed in a pulse-chase experiment in view of the rate of dislocation (*t* ~1/2~ = 2--5 min) in US11 cells ([@bib74]). In cells expressing US11 and shRNAs against GFP (control cells), HC disappears completely when proteasome inhibitors are not included ([Fig. 3 b](#fig3){ref-type="fig"}, [1](#fig1){ref-type="fig"}, lanes 2 and 3). In cells expressing SEL1L shRNA, the rate of degradation of class I MHC HC is much reduced ([Fig. 3 b](#fig3){ref-type="fig"}, [1](#fig1){ref-type="fig"}, lanes 8 and 9).

In the presence of the proteasome inhibitor ZL~3~VS, the deglycosylated class I MHC HC accumulates as the diagnostic intermediate that characterizes the dislocation reaction. In control shRNA US11 cells, complete conversion to the deglycosylated form of HC is seen after 30 min of chase (lane 6). In SEL1L knockdown cells, \>50% of HC remains in its fully glycosylated form. This persistence of HC is attributable to compromised dislocation, as only ∼50% of HC accesses the cytosolically disposed N-glycanase ([Fig. 3, b](#fig3){ref-type="fig"}, 1 \[lanes 11 and 12\], and c).

This impairment in dislocation is not caused by reduced levels of US11 in SEL1L knockdown cells, as US11 is expressed at comparable levels, nor is it caused by aberrant ER insertion and processing of US11, as determined by normal cleavage of US11\'s signal sequence ([@bib62]) in SEL1L knockdown cells ([Fig. 3 b](#fig3){ref-type="fig"}, [2](#fig2){ref-type="fig"}).

Because SEL1L is a mammalian homologue of yeast Hrd3p, we looked for possible parallels between the two systems that could account for the observed phenotype. Hrd1p, which is a yeast E3 ligase known to be necessary for degradation of some substrates ([@bib4]; [@bib10]; [@bib27]; [@bib39]; [@bib54]), is regulated by Hrd3p and destabilized in *Δhrd3* yeast ([@bib23]; [@bib59]). Therefore, we analyzed HRD1 levels in SEL1L knockdown cells to examine whether inhibition of dislocation is primarily caused by reduced levels of SEL1L or, alternatively, attributable to a reduction in HRD1 levels. We find that HRD1 is stable throughout the chase periods over which HC dislocation occurs ([Fig. 3 b](#fig3){ref-type="fig"}, [3](#fig3){ref-type="fig"}).

A comparable reduction of SEL1L levels in US2 cells ([Fig. 4 a](#fig4){ref-type="fig"}) has no observable effect on HC dislocation. In US2 cells exposed to proteasome inhibitor, we see conversion of almost all class I MHC HCs to the deglycosylated species after 30 min ([Fig. 4 b](#fig4){ref-type="fig"}, [1](#fig1){ref-type="fig"}, lane 6). In US2 cells, knockdown of SEL1L results in a rate of dislocation equal to that in control cells and yields a pattern noticeably distinct from that seen for the SEL1L knockdown in US11 cells ([Fig. 4](#fig4){ref-type="fig"}, b \[1\] and c). US2 levels are also comparable for control and SEL1L knockdown cells ([Fig. 4 b](#fig4){ref-type="fig"}, [2](#fig2){ref-type="fig"}). Unimpaired degradation in US2 cells of class I MHC HCs is consistent with the idea that US11 co-opts a conserved complex to catalyze degradation of class I MHC HC, whereas US2 utilizes a distinct pathway ([@bib44], [@bib45]; [@bib48]). This result is all the more striking because US2 and US11 target the same set of substrates, class I MHC products.

![**shRNAs targeting SEL1L do not impair US2-mediated dislocation of class I MHC HC.** (a) US2 cells were transduced with virus encoding shRNAs against GFP (control cells) or against SEL1L (knockdown cells) and analyzed for levels of SEL1L by immunoblotting with anti-SEL1L antibodies and anti-PDI antibodies as a loading control. (b) Control and knockdown cells were pulse-labeled for 10 min and chased for the indicated time points. Immunoprecipitation from SDS lysates for class I MHC HC (1) and US2 (2) were performed using respective antibodies. (c) Quantitation of the amount of glycosylated to deglycosylated HC from shRNA GFP (control) and shRNA SEL1L (knockdown) cells treated with ZL~3~VS.](jcb1750261f04){#fig4}

Given the homology of SEL1L to Hrd3p, it is likely that SEL1L plays a general role in glycoprotein turnover, similar to what was shown for the Der1p homologues of the Derlin proteins ([@bib44]; [@bib56]). Thus far, the only substrates that for their dislocation depend on Derlin-1 are class I MHC HCs in US11-expressing cells and US2 itself ([@bib44]). Overexpression and knockdowns of Derlin-2 and -3 have been reported to affect the half-life of α1 antitrypsin NHK ([@bib56]).

Therefore, we examined other model substrates of ER dislocation for their susceptibility to inhibition by a knockdown of SEL1L. We analyzed the effect of SEL1L shRNAs on the degradation of a mutant version of RI, RI~332~. The RI~332~ mutant lacks the C terminus of RI; unlike the very stable RI protein, the RI~332~ fragment has a half-life of ∼90 min ([@bib69]; [@bib15], [@bib16]). We chose RI~332~ as substrate because its mode of disposal includes an intermediate that is the product of N-glycanase activity ([@bib42]). We transiently transfected RI~332~ into HeLa cells, which had been stably transduced with shRNAs against either GFP or SEL1L ([Fig. 5 a](#fig5){ref-type="fig"}). SEL1L knockdown cells showed a reduction of SEL1L levels to 40% of controls. We transfected a GFP expression plasmid into both GFP shRNA and SEL1L shRNA HeLa cells as a transfection control, as well as a control for shRNA-mediated knockdown in the HeLa shRNA GFP control cells. The percentage of cells expressing GFP was equivalent (∼40%), but, as expected, the intensity of the GFP signal was much lower in GFP shRNA cells (unpublished data).

![**Dislocation of truncated RI (RI~332~) is impaired by shRNAs targeting SEL1L.** (a) HeLa cells were stably transduced with either shRNAS against GFP (control cells) or SEL1L (knockdown cells) and analyzed for levels of SEL1L by immunoblotting with anti-SEL1L antibodies and anti-PDI antibodies as a loading control. (b) Control and knockdown cells were transiently transfected with RI~332.~ 36 h after transfection, these cells were pulse-labeled for 20 min and chased for the indicated time points. Immunoprecipitation from SDS lysates were performed using anti-RI I antibodies. (c) The bar diagram shows quantitation of the experiment. Error bars represent the SD of three independent experiments.](jcb1750261f05){#fig5}

Two days after transfection, cells were harvested, pulsed for 20 min with \[^35^S\]methionine, and chased for 0, 90, and 180 min. Immunoprecipitation with anti-RI antibody retrieves both the truncated and wild-type RI. In control shRNA GFP HeLa cells, ∼90% of truncated RI~332~ is degraded after 180 min, whereas in SEL1L knockdown cells, we see a considerable stabilization of RI~332~; ∼40% of RI~332~ remains ([Fig. 5](#fig5){ref-type="fig"}, b \[lanes 3 and 6\] and c). The observed stabilization of RI~332~ is all the more noteworthy as the achieved stable knockdown of SEL1L in HeLa cells is ≥40% ([Fig. 5 a](#fig5){ref-type="fig"}). Wild-type RI (a stable protein in the ER) remains unaffected, and expression of SEL1L shRNA does not affect overall glycosylation as assessed by class I MHC HC and US11 maturation and glycosylation earlier.

Does SEL1L specifically interact with misfolded proteins in the ER?
-------------------------------------------------------------------

Because SEL1L has a long luminal domain with tetratricopeptide repeats (TPRs; Sel1 repeats of the TPR family; Fig. S1), a domain structure suggested to mediate protein--peptide interactions, we determined whether SEL1L interacts with misfolded proteins, and whether SEL1L can discriminate between properly folded and misfolded proteins. We examined association of RI~332~ with SEL1L by immunoprecipitating for SEL1L from extracts of cells transiently transfected with RI~332~ and lysed under mild conditions. We found that RI~332~ interacts with SEL1L ([Fig. 6 b](#fig6){ref-type="fig"}, lane 1), and we confirmed this interaction in re-immunoprecipitation experiments ([Fig. 6 b](#fig6){ref-type="fig"}, lane 2). We were unable to detect the full length, and presumably properly folded, form of RI in the re-immunoprecipitation, although the presence of trace amounts of full-length RI remains a possibility, as misfolded RI~332~ is in excess over endogenous RI ([Fig. 6 a](#fig6){ref-type="fig"}). As a second specificity control, we confirmed that the deglycosylated dislocation intermediate of RI~332~, which accumulates in the cytosol when cells are treated with proteasome inhibitor, does not interact with SEL1L ([Fig. 6](#fig6){ref-type="fig"} and Fig. S2, available at <http://www.jcb.org/cgi/content/full/jcb.200605196/DC1>).

![**SEL1L interacts with RI~332~ 293T cells transfected with RI~332~ that were pulse-labeled to steady-state for 5 h in the presence of 10 μM of the proteasome inhibitor ZL~3~VS.** Immunoprecipitations from digitonin lysates were performed with anti-SEL1L antibodies. The anti-SEL1L immunoprecipitate was either analyzed directly (b, lane 1) or reimmunoprecipitated sequentially using anti-RI I antibodies (b, lane 2) or anti-SEL1L antibodies (b, lane 3). (a) Input levels of endogenous RI and overexpressed RI~332~. Immunoprecipitates were resolved on a 12% SDS polyacrylamide gel. Asterisk represents a presumably processed version of RI~332~ in the ER.](jcb1750261f06){#fig6}

We transiently transfected the same HeLa cell lines that had been stably transduced with shRNAs targeting either SEL1L or GFP with TCRα. TCRα is likely degraded because of the unpaired charged residues in its transmembrane domain when its proper partner subunits (TCRβ and CD3 complex) are not coexpressed ([@bib14]). Cells were labeled for 20 min with \[^35^S\]methionine and chased for 0, 2, and 4 h ([Fig. 7 a](#fig7){ref-type="fig"}), and the amount of TCRα remaining at each time point was quantitated ([Fig. 7 b](#fig7){ref-type="fig"}). We see a moderate effect of a SEL1L knockdown on TCRα degradation; after 4 h of chase, 25% of TCRα remains in the shRNA GFP control cells, whereas in SEL1L knockdown cells, 35% remains ([Fig. 7 b](#fig7){ref-type="fig"}). The effect is likely to be less pronounced for TCRα than for RI~332~ because TCRα would be classified as misfolded because of recognition of unpaired charges in its transmembrane domain, whereas RI~332~ is an entirely luminal protein. From yeast, we know that the site of misfolding is crucial for the recruitment of specific substrate recognition proteins ([@bib2]; [@bib13]). Another explanation for the poor interference with TCRα degradation could be the level of SEL1L knockdown to no more than 40%. Interference with the degradation of TCRα might require a greater reduction in SEL1L levels than attained with the present knockdown strategies.

![**TCRα degradation is moderately slowed by shRNAs targeting SEL1L.** The same control and knockdown cells used in [Fig. 5](#fig5){ref-type="fig"} were transiently transfected with TCRα. 36 h after transfection these cells were pulse-labeled for 20 min and chased for the indicated time points. Immunoprecipitation from SDS lysates were performed using anti--TCRα-antibodies. (c) The histogram shows mean quantitation of two independent experiments.](jcb1750261f07){#fig7}

Discussion
==========

SEL1L is essential for dislocation of class I MHC molecules from the ER in cells that express US11. Upon reduction of the levels of the SEL1L protein, fully glycosylated, EndoH-sensitive class I MHC HCs accumulate in the ER. In contrast, the US2 pathway is not perturbed by reduction of SEL1L protein levels. These results underscore the relevance of other observations that place US11 and US2 in distinct pathways, e.g., based on their susceptibility to interference with Derlin-1 function; a Derlin-1^GFP^ fusion protein impairs degradation of class I MHC molecules via the US11-dependent, but not via the US2-dependent, pathway ([@bib44]).

There are several lines of evidence to suggest that US2 and US11 use different principles to accelerate degradation of class I MHC molecules, in addition to the aforementioned difference in Derlin-1 dependency. US2 must exploit features in its relatively short cytoplasmic tail, whereas tailless US11 remains dislocation-competent ([@bib21]; [@bib48]). The preference of the US2 and US11 pathways for folded and unfolded class I MHC molecules appears to be different ([@bib9]), as is the requirement for elements in the tail of the class I MHC molecules themselves ([@bib75]). Our data now establish that the US11, but not the US2, pathway is sensitive to a SEL1L knockdown. These distinctions are all the more remarkable given the similarities of the substrates targeted for degradation, the identical class I MHC HCs in the same parent cell line.

We also report that down-regulation of SEL1L affects the degradation of a RI fragment whose route of degradation is similar to what we have described for class I MHC products targeted by the HCMV immunoevasins ([@bib34]; [@bib42]). In the presence of proteasome inhibitors, a deglycosylated RI~332~ species, the product of N-glycanase digestion, is observed ([@bib42]). Our data, thus, support the notion that human SEL1L is the orthologue of yeast Hrd3p because reduction of SEL1L levels perturbs the degradation of a misfolded substrate, RI~332~.

We conclude that SEL1L and its associated partners operate in a pathway that is neither restricted to class I MHC products, nor strictly dependent on the involvement of virus-encoded proteins. The concept of physically extracting proteins from the ER and their delivery to the cytosolic proteasome achieves the compartmentalization required to spare nascent and properly folded ER proteins from premature degradation. The advantages of studying the pathways for the HCMV US2 and US11 proteins are the speed with which degradation occurs and the involvement of well-characterized substrates, the class I MHC products. The available antibodies allow an easy distinction between various folding intermediates, and the occurrence of the tell-tale deglycosylated degradation intermediate is an accurate reporter for its localization and for the dislocation reaction per se ([@bib74],[@bib75]). We have taken advantage of the fact that US2 and US11 attract very similar substrates in one and the same cell, yet apparently do so by mechanistically different pathways ([@bib21]; [@bib44]; [@bib48]).

This does raise the question, however, of whether the results obtained for these HCMV immunoevasins and class I MHC substrates can be extrapolated to other substrates, and to pathways that operate independently of viral accessories.

To our knowledge, the observation that SEL1L is involved in the degradation of RI~332~, a known dislocation substrate, is the first example for mammalian cells that directly places SEL1L in a pathway of protein degradation. The dominant-negative version of Derlin-1, Derlin-1^GFP^, had no effect on RI~332~ degradation (unpublished data), making the mammalian degradation pathways even more complex. The different degradation pathways that, in yeast, process distinct types of substrates (luminally vs. cytoplasmically exposed proteins) likely operate in mammals, too, but involve more factors that comprise the different complexes. In addition to the multiple Derlin proteins, ubiquitin ligases, and lectins involved in mammalian ER degradation, there is an additional SEL1L-like protein in mammals that bears homology to Hrd3p (Fig. S1). Whether this protein binds to HRD1 and participates in the degradation of misfolded proteins remains to be determined.

In yeast, substrates that require Der1p for degradation require Hrd1p/Hrd3p and usually belong to the set of completely luminal substrates. In mammals, depending on the substrate, Derlin-1 and SEL1L can act in concert with each other, as we show for class I MHC HC, but SEL1L can also assist in the degradation of substrates independently of Derlin-1, as is the case for RI~332~. A recent study suggests that, in yeast, Hrd3p and Der1p can recruit substrates independently of each other ([@bib25]).

We also examined a substrate that is recognized as misfolded by means of charged residues in its transmembrane domain, TCRα. We observed modest stabilization when SEL1L expression is compromised. The lesser effect on this substrate compared with RI~332~, which is an entirely luminal substrate, further suggests that the nature of the substrate determines recruitment of an otherwise conserved complex. We cannot exclude that different degradation substrates require different levels of SEL1L. Perhaps TCRα degradation usually proceeds in the presence of very few SEL1L molecules.

The ER machinery involved in recognition of substrates is likely to be specific for certain substrates, but the details of recognition of misfolded substrates in yeast are no better resolved than in mammalian cells. In yeast, Yos9p, a putative lectin protein, is involved in the degradation of a membrane-bound version of CPY\* ([@bib12]) and might be involved in identifying and targeting substrates for degradation ([@bib6]; [@bib40]; [@bib66]). A recent study suggests that proteins that are misfolded in yeast bind to Hrd3p, which itself binds to Yos9p. Yos9p then ensures that only terminally misfolded proteins are being degraded ([@bib24]). Another avenue to identification of misfolded glycoproteins might be through their high-mannose--containing, N-linked glycan modifications ([@bib29]). Mannose residues are trimmed in the ER by the enzyme α-mannosidase I ([@bib33]; [@bib76]), generating a Man8GlcNac2 tag implicated in targeting glycoproteins for degradation ([@bib18]). Proteins with this tag bind to calnexin and other lectins, the ER degradation-enhancing mannosidase-like (EDEM) proteins, EDEM1 and EDEM2 ([@bib32], [@bib33]; [@bib49]; [@bib57]), which then target some glycoproteins for degradation ([@bib53]; [@bib2]; [@bib56]) There is a mammalian orthologue of Yos9p, OS-9, whose function is unknown but might be critical in degradation of certain substrates.

Similar to EDEM, SEL1L might be involved in substrate recognition and bind to a subset of misfolded proteins. SEL1L is remarkably conserved, and contains several repetitive structural and functional domains (sel1-like repeats of the TPR family) and a type II fibronectin domain in its large luminal part that could bind to chaperones or misfolded proteins. Alternatively, SEL1L might recruit substrate recognition proteins such as EDEM or OS-9 through its type II fibronectin domain at its N terminus. In yeast, Hrd3p\'s N-terminal domain is essential for its function in ER degradation, and its central region required for interaction with Hrd1p ([@bib22]).

SEL1L forms a 1:1 stoichiometric complex with HRD1 in mammalian cells ([@bib45]), but until now, SEL1L\'s direct involvement in protein degradation has not been shown. Thus, we conclude that SEL1L, based on its associated partners, its direct involvement in glycoprotein degradation, and its structural relationship to yeast Hrd3p, helps select proteins for entry into a degradative pathway. Our data provide the first functional evidence to support the notion that SEL1L is indeed the orthologue of yeast Hrd3p.

Materials and methods
=====================

Antibodies, DNA constructs, and cell lines
------------------------------------------

Anti-HC, anti-US2, anti-US11, anti--Derlin-1, anti--Derlin-2, and anti-SEL1L antibodies have been described previously ([@bib67]; [@bib26]; [@bib46]; [@bib44], [@bib45]).

Anti-RI~332~ antibodies and the RI~332~ DNA construct were a gift from N.E. Ivessa (University of Vienna, Vienna, Austria) and G. Kreibich (New York University Medical Center, New York, NY), anti-TCRα antibodies were purchased from Sigma-Aldrich, and anti-HRD1 antibodies were a gift from E. Wiertz (Leiden University, Leiden, Netherlands; [@bib39]).

The TCRα expression construct was described previously ([@bib35]).

For stable shRNA expression, the pRETRO-SUPER vector was used ([@bib11]).

U373-MG astrocytoma/glioblastoma cells, US2, US11, 293T, and HeLa cells were cultured as previously described ([@bib62]; [@bib46]).

MM1.S cells were cultured in RPMI containing 10% FCS.

Metabolic labeling, immunoprecipitation, endoglycosidase H digestion, gel electrophoresis, immunoblotting, and transient transfections
--------------------------------------------------------------------------------------------------------------------------------------

These procedures were similar to those described in [@bib45]. Treatment of cells with the proteasome inhibitor ZL~3~VS has been previously described ([@bib63]). Analysis of class I MHC HC stability in US11 and US2 cells, pulse-labeling, cell lysis (SDS and digitonin), and re-immunoprecipitations have been previously described ([@bib46]). NEM (N-ethylmaleimide) was included in digitonin and SDS lysis at a concentration of 2.5 mM. SDS PAGE has been previously described ([@bib60]).

293T cells were transiently transfected with Trans-IT (Takara Mirus Bio) according to the manufacturer, using 2--5 μg of DNA for transient transfections and 10 μg of total DNA for virus production in 10-cm dishes. HeLa cells were transiently transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer, using 2--5 μg for transient transfections in 10-cm dishes.

Immunoprecipitates were treated with EndoH according to the manufacturer (New England Biolabs).

The program ImageJ (National Institutes of Health) was used for quantitating bands on film.

SEL1L knockdown
---------------

19-nt target sequences in SEL1L were chosen according to the online design software available from the Whitehead Institute webpage (<http://jura.wi.mit.edu/siRNAext/>). Sense and antisense strands were annealed to form the shRNA template insert and ligated into the retroviral vector pRETRO SUPER ([@bib11]) to generate shRNA construct s2 for stable shRNA expression and for transient transfection (19mer sequences; GGCTATACTGTGGCTAGAA and TTCTAGCCACAGTATAGCC, respectively). As a control, the unrelated construct (GFP shRNA) targeting the enhanced GFP reporter was used ([@bib45]). All constructs were sequence-confirmed and used for virus production in HEK 293T cells ([@bib64]). pRETRO-transduced U373 cells and HeLa cells were selected with 0.375 μg/ml and 1 μg/ml puromycin, respectively, as previously described ([@bib45]).

Online supplemental material
----------------------------

Fig. S1 shows a schematic of the Hrd3p homologues in mammals. Fig. S2 shows SEL1L interacting with RI~332~ 293T cells transfected with RI~332~. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.200605196/DC1>.
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